問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

林錫銘Lin, Shi-Ming
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • lsmpaicyto@cgmh.org.tw

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林錫銘

List

56Cases

2019-08-01 - 2025-06-30

Phase II

Completed
A Phase II Randomized Placebo Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    tablets

Participate Sites
7Sites

Terminated7Sites

2017-11-01 - 2021-05-20

Phase III

Completed
A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    unresectable HCC

  • Test Drug

    Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-10-01 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-01-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-15 - 2026-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-30 - 2026-09-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
9Sites

Recruiting9Sites

2015-05-01 - 2020-04-30

Phase I/II

Completed
A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis.

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

陳三奇
Taipei Veterans General Hospital

2021-03-01 - 2026-12-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2022-02-16 - 2026-12-31

Others

Active
A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
9Sites

Recruiting9Sites

2014-04-20 - 2016-05-20

Phase II

Completed
Randomized, Open Label, Phase 2 Trial of ADI-PEG 20 plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of General Surgery

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB